Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Jeannette M. Schenk, Gregory S. Calip, Catherine M. Tangen, Phyllis Goodman, J. Kellogg Parsons, Ian M. Thompson, Alan R. Kristal

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The authors conducted a cohort study of nonsteroidal antiinflammatory drug (NSAID) use and risk of symptomatic benign prostatic hyperplasia (BPH), using data from 4,735 men without BPH at baseline in the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH (n = 471) was defined as medical or surgical treatment or at least 2 International Prostate Symptom Score (I-PSS) values greater than or equal to 15. Proportional hazards models using time-dependent exposure for NSAID use were employed to estimate covariate-adjusted associations of NSAID-related medical conditions and NSAID use with BPH risk. Arthritis, other inflammation-related musculoskeletal conditions, and headaches were associated with increased BPH risk (hazard ratio (HR) = 1.77 (95% confidence interval (CI): 1.37, 2.29), HR = 1.57 (95% CI: 1.14, 2.17), and HR = 1.40 (95% CI: 1.09, 1.80), respectively). Use of any NSAID, use of aspirin, and use of nonaspirin NSAIDs were associated with significant increases in BPH risk (HR = 1.21 (95% CI: 1.01, 1.46), HR = 1.20 (95% CI: 1.00, 1.45), and HR = 1.34 (95% CI: 1.07, 1.69), respectively). Control for indications for NSAID use, including baseline I-PSS, attenuated the associations slightly, but all became nonsignificant. Among men with no indications for NSAID use, the hazard ratio for any NSAID use was 1.06 (95% CI: 0.82, 1.38). The modest associations of NSAID use with BPH risk in this cohort were probably due to confounding by indication, and NSAID use was not associated with BPH risk.

Original languageEnglish (US)
Pages (from-to)156-163
Number of pages8
JournalAmerican Journal of Epidemiology
Volume176
Issue number2
StatePublished - Jul 15 2012
Externally publishedYes

Fingerprint

Prostatic Hyperplasia
Prostatic Neoplasms
Anti-Inflammatory Agents
Confidence Intervals
Pharmaceutical Preparations
Prostate
Odds Ratio
Non-Steroidal Anti-Inflammatory Agents
Proportional Hazards Models
Aspirin
Arthritis
Headache
Cohort Studies
Placebos
Inflammation

ASJC Scopus subject areas

  • Epidemiology

Cite this

Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia : results from the prostate cancer prevention trial. / Schenk, Jeannette M.; Calip, Gregory S.; Tangen, Catherine M.; Goodman, Phyllis; Parsons, J. Kellogg; Thompson, Ian M.; Kristal, Alan R.

In: American Journal of Epidemiology, Vol. 176, No. 2, 15.07.2012, p. 156-163.

Research output: Contribution to journalArticle

Schenk, Jeannette M. ; Calip, Gregory S. ; Tangen, Catherine M. ; Goodman, Phyllis ; Parsons, J. Kellogg ; Thompson, Ian M. ; Kristal, Alan R. / Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia : results from the prostate cancer prevention trial. In: American Journal of Epidemiology. 2012 ; Vol. 176, No. 2. pp. 156-163.
@article{564e9b55570d4d52ae29a6b31c1cf44e,
title = "Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.",
abstract = "The authors conducted a cohort study of nonsteroidal antiinflammatory drug (NSAID) use and risk of symptomatic benign prostatic hyperplasia (BPH), using data from 4,735 men without BPH at baseline in the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH (n = 471) was defined as medical or surgical treatment or at least 2 International Prostate Symptom Score (I-PSS) values greater than or equal to 15. Proportional hazards models using time-dependent exposure for NSAID use were employed to estimate covariate-adjusted associations of NSAID-related medical conditions and NSAID use with BPH risk. Arthritis, other inflammation-related musculoskeletal conditions, and headaches were associated with increased BPH risk (hazard ratio (HR) = 1.77 (95{\%} confidence interval (CI): 1.37, 2.29), HR = 1.57 (95{\%} CI: 1.14, 2.17), and HR = 1.40 (95{\%} CI: 1.09, 1.80), respectively). Use of any NSAID, use of aspirin, and use of nonaspirin NSAIDs were associated with significant increases in BPH risk (HR = 1.21 (95{\%} CI: 1.01, 1.46), HR = 1.20 (95{\%} CI: 1.00, 1.45), and HR = 1.34 (95{\%} CI: 1.07, 1.69), respectively). Control for indications for NSAID use, including baseline I-PSS, attenuated the associations slightly, but all became nonsignificant. Among men with no indications for NSAID use, the hazard ratio for any NSAID use was 1.06 (95{\%} CI: 0.82, 1.38). The modest associations of NSAID use with BPH risk in this cohort were probably due to confounding by indication, and NSAID use was not associated with BPH risk.",
author = "Schenk, {Jeannette M.} and Calip, {Gregory S.} and Tangen, {Catherine M.} and Phyllis Goodman and Parsons, {J. Kellogg} and Thompson, {Ian M.} and Kristal, {Alan R.}",
year = "2012",
month = "7",
day = "15",
language = "English (US)",
volume = "176",
pages = "156--163",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia

T2 - results from the prostate cancer prevention trial.

AU - Schenk, Jeannette M.

AU - Calip, Gregory S.

AU - Tangen, Catherine M.

AU - Goodman, Phyllis

AU - Parsons, J. Kellogg

AU - Thompson, Ian M.

AU - Kristal, Alan R.

PY - 2012/7/15

Y1 - 2012/7/15

N2 - The authors conducted a cohort study of nonsteroidal antiinflammatory drug (NSAID) use and risk of symptomatic benign prostatic hyperplasia (BPH), using data from 4,735 men without BPH at baseline in the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH (n = 471) was defined as medical or surgical treatment or at least 2 International Prostate Symptom Score (I-PSS) values greater than or equal to 15. Proportional hazards models using time-dependent exposure for NSAID use were employed to estimate covariate-adjusted associations of NSAID-related medical conditions and NSAID use with BPH risk. Arthritis, other inflammation-related musculoskeletal conditions, and headaches were associated with increased BPH risk (hazard ratio (HR) = 1.77 (95% confidence interval (CI): 1.37, 2.29), HR = 1.57 (95% CI: 1.14, 2.17), and HR = 1.40 (95% CI: 1.09, 1.80), respectively). Use of any NSAID, use of aspirin, and use of nonaspirin NSAIDs were associated with significant increases in BPH risk (HR = 1.21 (95% CI: 1.01, 1.46), HR = 1.20 (95% CI: 1.00, 1.45), and HR = 1.34 (95% CI: 1.07, 1.69), respectively). Control for indications for NSAID use, including baseline I-PSS, attenuated the associations slightly, but all became nonsignificant. Among men with no indications for NSAID use, the hazard ratio for any NSAID use was 1.06 (95% CI: 0.82, 1.38). The modest associations of NSAID use with BPH risk in this cohort were probably due to confounding by indication, and NSAID use was not associated with BPH risk.

AB - The authors conducted a cohort study of nonsteroidal antiinflammatory drug (NSAID) use and risk of symptomatic benign prostatic hyperplasia (BPH), using data from 4,735 men without BPH at baseline in the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH (n = 471) was defined as medical or surgical treatment or at least 2 International Prostate Symptom Score (I-PSS) values greater than or equal to 15. Proportional hazards models using time-dependent exposure for NSAID use were employed to estimate covariate-adjusted associations of NSAID-related medical conditions and NSAID use with BPH risk. Arthritis, other inflammation-related musculoskeletal conditions, and headaches were associated with increased BPH risk (hazard ratio (HR) = 1.77 (95% confidence interval (CI): 1.37, 2.29), HR = 1.57 (95% CI: 1.14, 2.17), and HR = 1.40 (95% CI: 1.09, 1.80), respectively). Use of any NSAID, use of aspirin, and use of nonaspirin NSAIDs were associated with significant increases in BPH risk (HR = 1.21 (95% CI: 1.01, 1.46), HR = 1.20 (95% CI: 1.00, 1.45), and HR = 1.34 (95% CI: 1.07, 1.69), respectively). Control for indications for NSAID use, including baseline I-PSS, attenuated the associations slightly, but all became nonsignificant. Among men with no indications for NSAID use, the hazard ratio for any NSAID use was 1.06 (95% CI: 0.82, 1.38). The modest associations of NSAID use with BPH risk in this cohort were probably due to confounding by indication, and NSAID use was not associated with BPH risk.

UR - http://www.scopus.com/inward/record.url?scp=84866245273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866245273&partnerID=8YFLogxK

M3 - Article

C2 - 22759721

AN - SCOPUS:84866245273

VL - 176

SP - 156

EP - 163

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 2

ER -